Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
crispr
4
×
editas medicine
life sciences
national blog main
4
×
biotech
national top stories
boston
cancer
crispr-cas9
gene editing
katrine bosley
national
new york blog main
san francisco blog main
san francisco top stories
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
allergan
andrew oxtoby
babies
beam therapeutics
biotech week boston
boulder/denver blog main
boulder/denver top stories
breakup
bridge bio pharma
bristol-myers squibb
broad institute
bwb
ceo
cindy perettie
clinical hold
clinical study
clinical trials
combination
commissioner
What
medicine
4
×
crispr
cas
ceo
editas
editing
gene
katrine
allergan
benefiting
big
bio
blessing
bosley
bosley's
bosley’s
boston
bridge
bucks
cancer
cells
check
clinical
coming
crime
cusp
defect
depart
departure
diagnostics
drive
edited
exit
experimental
fears
flag
genetic
glimcher
groundbreaking
guardian
Language
Current search:
medicine
×
crispr
×
" national blog main "
×
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells